Drug intelligence / Profile preview

d-cycloserine + mifepristone

Development stage: Preclinical
Lead developer: Streptomyces orchidaceus (original natural source)
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **d-cycloserine**, an antibiotic used to treat tuberculosis and urinary tract infections, which also acts as a partial agonist at NMDA receptors and has been explored for anxiety disorders and PTSD. **Mifepristone** is a glucocorticoid receptor antagonist used primarily for medical termination of pregnancy and treating Cushing's syndrome. The combination is not a standard therapeutic regimen but has been explored in research contexts for PTSD and other conditions.

Other names: DCS and mifepristoneMedication Enhanced Rapid Therapy

Targets

PR (Progesterone receptor)GRIN2C (NMDA receptor subunit 2C)GR (Glucocorticoid receptor)AR (Adrenergic receptors)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on d-cycloserine + mifepristone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on d-cycloserine + mifepristone.

Explore the full profile